QUOTED. 13 January 2021. John Babitt.
EY expects a very active M&A activity for medtechs in 2021 – but also thinks 2020 was impressive for the sector, said the firm’s Americas medtech leader John Babitt.
“We believe 2020 was an impressive year for medtech, in spite of procedures getting postponed, as M&A firepower approached a historical high for the industry of nearly $500bn." – John Babitt, Americas medtech leader, EY
Click here for a free trial of Medtech Insight